We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 532345

CAS#: 627034-85-9

Description: NF449 is a potent purinergic receptor antagonist that displays high selectivity for P2X1 (IC50 values are 0.28, 0.69, 120, 1820, 47000 and > 300000 nM for rP2X1, rP2X1+5, rP2X2+3, rP2X3, rP2X2 and P2X4 receptors respectively). NF449 provides antithrombotic protection in vivo. NF449 also acts as a Gsα-selective antagonist.

Price and Availability

Size Price Shipping out time Quantity
5mg USD 220 2 Weeks
10mg USD 380 2 Weeks
50mg USD 1030 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-10-30. Prices are subject to change without notice.

NF449, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 532345
Name: NF449
CAS#: 627034-85-9
Chemical Formula: C41H24N6Na8O29S8
Exact Mass: 1503.7535
Molecular Weight: 1505.05
Elemental Analysis: C, 32.72; H, 1.61; N, 5.58; Na, 12.22; O, 30.83; S, 17.04

Synonym: NF449; NF 449; NF-449.

IUPAC/Chemical Name: 4,4',4'',4'''-[Carbonylbis(imino-5,1,3-benzenetriyl-bis(carbonylimino))]tetrakis-1,3-benzenedisulfonic acid, octasodium salt


InChi Code: InChI=1S/C41H32N6O29S8.8Na/c48-37(44-29-5-1-25(77(53,54)55)15-33(29)81(65,66)67)19-9-20(38(49)45-30-6-2-26(78(56,57)58)16-34(30)82(68,69)70)12-23(11-19)42-41(52)43-24-13-21(39(50)46-31-7-3-27(79(59,60)61)17-35(31)83(71,72)73)10-22(14-24)40(51)47-32-8-4-28(80(62,63)64)18-36(32)84(74,75)76;;;;;;;;/h1-18H,(H,44,48)(H,45,49)(H,46,50)(H,47,51)(H2,42,43,52)(H,53,54,55)(H,56,57,58)(H,59,60,61)(H,62,63,64)(H,65,66,67)(H,68,69,70)(H,71,72,73)(H,74,75,76);;;;;;;;/q;8*+1/p-8

SMILES Code: O=C(NC1=CC(C(NC2=CC=C(S(=O)([O-])=O)C=C2S(=O)([O-])=O)=O)=CC(C(NC3=CC=C(S(=O)([O-])=O)C=C3S(=O)([O-])=O)=O)=C1)NC4=CC(C(NC5=CC=C(S(=O)([O-])=O)C=C5S(=O)([O-])=O)=O)=CC(C(NC6=CC=C(S(=O)([O-])=O)C=C6S(=O)([O-])=O)=O)=C4.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Nishimura Y, McLaughlin NP, Pan J, Goldstein S, Hafenstein S, Shimizu H, Winkler JD, Bergelson JM. The Suramin Derivative NF449 Interacts with the 5-fold Vertex of the Enterovirus A71 Capsid to Prevent Virus Attachment to PSGL-1 and Heparan Sulfate. PLoS Pathog. 2015 Oct 2;11(10):e1005184. doi: 10.1371/journal.ppat.1005184. eCollection 2015 Oct 2. PubMed PMID: 26430888; PubMed Central PMCID: PMC4592248.

2: Farmer LK, Schmid R, Evans RJ. Use of chimeras, point mutants, and molecular modeling to map the antagonist-binding site of 4,4',4″,4‴-(carbonylbis-(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakisbenz ene-1,3-disulfonic acid (NF449) at P2X1 receptors for ATP. J Biol Chem. 2015 Jan 16;290(3):1559-69. doi: 10.1074/jbc.M114.592246. Epub 2014 Nov 25. PubMed PMID: 25425641; PubMed Central PMCID: PMC4340402.

3: El-Ajouz S, Ray D, Allsopp RC, Evans RJ. Molecular basis of selective antagonism of the P2X1 receptor for ATP by NF449 and suramin: contribution of basic amino acids in the cysteine-rich loop. Br J Pharmacol. 2012 Jan;165(2):390-400. doi: 10.1111/j.1476-5381.2011.01534.x. PubMed PMID: 21671897; PubMed Central PMCID: PMC3268193.

4: Su TR, Hung YS, Huang SS, Su HH, Su CC, Hsiao G, Chen YH, Lin MJ. Study of the reversal effect of NF449 on neuromuscular blockade induced by d-tubocurarine. Life Sci. 2011 Jun 6;88(23-24):1039-46. doi: 10.1016/j.lfs.2011.03.013. Epub 2011 Mar 28. PubMed PMID: 21453711.

5: Krejci P, Murakami S, Prochazkova J, Trantirek L, Chlebova K, Ouyang Z, Aklian A, Smutny J, Bryja V, Kozubik A, Wilcox WR. NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells. J Biol Chem. 2010 Jul 2;285(27):20644-53. doi: 10.1074/jbc.M109.083626. Epub 2010 May 3. PubMed PMID: 20439987; PubMed Central PMCID: PMC2898326.

6: Hechler B, Magnenat S, Zighetti ML, Kassack MU, Ullmann H, Cazenave JP, Evans R, Cattaneo M, Gachet C. Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis -benzene-1,3-disulfonic acid octasodium salt]. J Pharmacol Exp Ther. 2005 Jul;314(1):232-43. Epub 2005 Mar 25. PubMed PMID: 15792995.

7: Rettinger J, Braun K, Hochmann H, Kassack MU, Ullmann H, Nickel P, Schmalzing G, Lambrecht G. Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist. Neuropharmacology. 2005 Mar;48(3):461-8. PubMed PMID: 15721178.

8: Kassack MU, Braun K, Ganso M, Ullmann H, Nickel P, Böing B, Müller G, Lambrecht G. Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist. Eur J Med Chem. 2004 Apr;39(4):345-57. PubMed PMID: 15072843.

9: Hülsmann M, Nickel P, Kassack M, Schmalzing G, Lambrecht G, Markwardt F. NF449, a novel picomolar potency antagonist at human P2X1 receptors. Eur J Pharmacol. 2003 May 30;470(1-2):1-7. PubMed PMID: 12787824.

10: Braun K, Rettinger J, Ganso M, Kassack M, Hildebrandt C, Ullmann H, Nickel P, Schmalzing G, Lambrecht G. NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2001 Sep;364(3):285-90. PubMed PMID: 11521173.